

POISE 'Psoriatic Oligoarthritis Intervention with Symptomatic therapy'

EudraCT: 2018-001085-42

The POISE trial opened on 17 April 2019 in Oxford and 19 September 2019 in Bath. The study remained open until 16 July 2020 as planned. During this period, only one patient was recruited and that patient was randomised to the standard care arm. They started on csDMARD therapy but were lost to follow up shortly after and upon review of their clinical notes, appear to have stopped treatment with csDMARDs of their own accord. No serious adverse events were reported for this participant before their withdrawal.

No further recruitment activity took place and the study was abandoned.